Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

69.95 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,837
Open 69.95
Bid (Size) 69.98 (13)
Ask (Size) 70.05 (7)
Prev. Close 69.95
Today's Range 69.95 - 69.95
52wk Range 61.24 - 87.67
Shares Outstanding N/A
Dividend Yield 3.00%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is the Market Bullish or Bearish on AstraZeneca?
Via Benzinga
AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion
AstraZeneca inks a multibillion-dollar deal with CSPC to co-develop AI-driven therapies for chronic and immune diseases, boosting its presence in China. 
Via Benzinga

Performance

YTD
+6.2%
+6.2%
1 Month
-0.7%
-0.7%
3 Month
-5.6%
-5.6%
6 Month
+5.0%
+5.0%
1 Year
-11.9%
-11.9%

More News

Read More
AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate, But Retail’s In No Mood To Cheer
Via Stocktwits
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Looking Into AstraZeneca's Recent Short Interest
Via Benzinga
IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA
Via MarketBeat
Jensen Huang's Quantum Support Boosts IonQ's Growth Plans: Nvidia Partnership, Oxford Ionics Deal Lead Needham To Reiterate 'Buy'
Via Benzinga
What's Going On With IonQ Shares Monday?
Via Benzinga
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season
Via Benzinga
Is D-Wave Quantum a Better Quantum Computing Stock to Buy Than IonQ?
Via The Motley Fool
AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO
Via Benzinga
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma
Via Investor's Business Daily
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
From AstraZeneca
Via Business Wire
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
From AstraZeneca
Via Business Wire
Why Tempus AI Stock Plummeted This Week
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Artificial Intelligence Stock Tempus AI Is Tumbling Today
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
The Promise of Quantum Computing
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
From AstraZeneca
Via Business Wire
3 Promising Growth Stocks You Can Buy for Less Than $100
Via The Motley Fool
How Does D-Wave Stack Up Against Quantum Competitors?
Via MarketBeat
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
From AstraZeneca
Via Business Wire
George Soros Loads Up On First Solar Calls: What Does He Know That Wall Street Doesn't?
Via Benzinga
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price
Via Investor's Business Daily
Exposures Product Safety

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 69.95
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 06/20/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.